Enliven® ENROLMENT FORM

Rheumatology

■ New enrolment

Renewal

Fax 1-888-987-2201

Enrol in En/liven®
1.877.9ENBREL (1.877.936.2735)
enbrel.ca



ENB1579-AMG-E-16

Patient Information	7
	Female Male
First name	, , , , , , , , , , , , , , , , , , , ,
Last name	Date of birth (dd/mm/yyyy)
Do you have health insurance coverage	ge? Private Public Both
Contact Information	
Preferred phone	Alternate phone
Preferred time to call	Afternoon
Preferred language	
Address	
City	Province Postal code
Email	
from Adjuvant, [®] acting on behalf of A and updates relating to my enrolment may withdraw my consent to such coi to Adjuvant, Inc. at: 901 King St. Wes via email at enliven@adjuvantz.com.	e to receive, electronically, communications mgen Canada, Inc. containing information in the En <i>liven</i> Program. I understand that I nmunications at any time by providing notice t, Suite 300, Toronto, Ontario, M5V 3H5 or
on the reverse of this form and conser personal information, including person their authorized agents and service pro	It I have read and understand the information to the collection, use and disclosure of my all health information, by Adjuvant,, Amgen and widers as explained. I further consent to being nt, Amgen or their authorized agents for the
confidential surveys about the Progra	n time to time for the purpose of completing m. I understand that I may withdraw my consent by time by contacting the En <i>liven</i> Program.
	(/ /)

Physician Information	
Physician name Site # (if applicable) Phone Fax	Other information/office stamp
Patient Medical Information	
Diagnosis Adult rheumatoid arthritis (RA) Psoriatic arthritis (PsA) Ankylosing spondylitis (AS) Juvenile idiopathic arthritis (JIA) Injection training Request an Enliven Yes No nurse to train this patient on self-injection	ENBREL Autoinjector syringe (lyophilized powder) (50 mg/mL) Patient to start ENBREL: At this time OR Pending test results Prescription Information (optional)
Allergies?* Yes No	Duration: Repeat(s): Other instructions:
TB test required? Yes No ENBREL® dosage Adult rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis 50 mg SC per week Juvenile idiopathic arthritis (ages 4 to 17 years) 0.8 mg/kg SC per week (up to a maximum of 50 mg per week) * Required for nursing service only.	I authorize Adjuvant, to be my designated agent to forward the prescription indicated above, by fax or other mode of delivery, to the Program specialty pharmacy or to the pharmacy chosen by the above-named patient. This prescription represents the original of the prescription drug order. The pharmacy chosen by the Program is the only intended recipient and there are no others. The original prescription has been invalidated and securely filed and it will not be transmitted elsewhere at another time. (/ /) Physician signature Date (dd/mm/yyyy)

Consent

We respect your right to privacy. The Enliven Program ("Program") is sponsored by Amgen Canada Inc. ("Amgen") and administered by Adjuvant_z. (a division of GMD) on behalf of Amgen. The personal information that you and/or your doctor provide to the Program, including your name, contact information, and prescription information, will be used to provide you with Program services, including locating reimbursement or insurance coverage on your behalf, administering, training or assisting in therapy (e.g. self-injection training), and to allow Adjuvant_z to conduct confidential surveys, from time to time, about the Program. Your personal information may be combined with the information of others who participate in the Program in order to generate aggregated data that do not contain identifying information ("Aggregated Data"). Aggregated Data may be used by Amgen and its service providers to improve and/or refine the Program, to design and implement other patient programs and for research purposes, including the identification of trends such as product utilization, adherence or outcomes.

For these sole purposes, Adjuvant, may share your personal information, on a confidential basis, with Amgen and/or Amgen's agents and service providers (e.g. information technology providers). If, from time to time, another service provider is appointed by Amgen to administer the Program, your personal information will be transferred to this service

provider to ensure the continuity of the Program services to you. Please note that Amgen and its service providers may store or process your personal information outside of Canada (including the United States) where local laws may require the disclosure of personal information to governmental authorities under circumstances that are different than those that apply in Canada. In addition, your personal information may be disclosed to third parties when permitted or required by applicable laws, court orders, or government regulations (collectively, "Applicable Laws"). Your personal information will be retained only as long as is needed to fulfil the purposes for which it was collected and in order to comply with Applicable Laws. Industry standard safeguards will be used to protect the security of the personal information that is collected. You may contact Adjuvantz's Privacy Officer at 1-888-706-4717, email to info@adjuvantz.com or write to 901 King St. West, Suite 300, Toronto, Ontario, M5V 3H5 at any time to update or access your personal information, modify or withdraw your consent (in part or in full), express a privacy-related concern, or to inquire about our privacy practices for the Program. Please note that if you modify or withdraw your consent, your ability to receive the Program services may be limited. Eligibility criteria and availability of financial assistance may change at any time without prior notice and are at the sole and absolute discretion of the Enliven Program.

This document may contain private and confidential information and is intended only for the person(s) named on the reverse. If you are not a named addressee, you should not disseminate, distribute or copy this document. If you have received this document by mistake, please notify the sender immediately and then destroy this document. We thank you for your cooperation and assistance.

ENBREL® is manufactured by Immunex Corporation and marketed by Amgen Canada Inc.

ENBREL® and Enliven® are registered trademarks of Immunex Corporation and SureClick® is a registered trademark of Amgen Inc., all used with permission.

© 2016 Amgen Canada Inc. All rights reserved.







